PABAF.US Patrys Limited
- Market cap
- USD 42.5M
- P/E
- -
- P/B
- 38.37x
- ROE
- -36.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PABAF.US undervalued?
Graham numberThe Graham number of Patrys Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Patrys Limited fundamental analysis
No fundamental analysis for Patrys Limited yet.
Patrys Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the bi…
Full company profilePatrys Limited financial statements
Patrys Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 27.5K | - | - | - | - |
| Gross Profit | 27.5K | - | - | - | - |
| Operating Income | -10.1M | -9.96M | -4.92M | -3.54M | -3.42M |
| EBITDA | -10.1M | -9.91M | -4.87M | -3.49M | -3.42M |
| Net Income | -6.78M | -7.06M | -3.54M | -3.01M | -3.42M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Balance Sheet | |||||
| Total Assets | 14.0M | 7.52M | 4.16M | 1.74M | 10.2M |
| Total Liabilities | 543K | 687K | 691K | 1.01M | 919K |
| Shareholders' Equity | 13.4M | 6.84M | 3.47M | 733K | 9.28M |
| Cash & Short-term Investments | 7.82M | 3.05M | 2.24M | 742K | 3.36M |
| Cash Flow | |||||
| Capital Expenditure | 2.29K | 0.00 | 3.24K | 0.00 | 3.85K |
| Free Cash Flow | -8.68M | -5.78M | -1.82M | -1.77M | -2.17M |
| Ratios | |||||
| ROE | -50.5% | -103.3% | -102.0% | -411.2% | -36.8% |
| ROA | -48.5% | -93.8% | -85.0% | -173.3% | -33.5% |
| Net Profit Margin | -24,655.9% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Patrys Limited dividends
Patrys Limited has not paid dividends in the last 6 fiscal years.
Who owns Patrys Limited
- Insiders 31.54%
- Institutions 0.00%
- Public & others 68.46%
- Shares outstanding 709M
- Free float 317M
Patrys Limited company profile
- Company name
- Patrys Limited
- Ticker
- PABAF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 168 Stirling Highway, Nedlands, WA, Australia, 6009
- Phone
- 61 8 6165 8858
- Website
- patrys.com
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
Patrys Limited management
3- Dr. Samantha South GAICD, MBA, Ph.D.Chief Executive Officer
- Mr. Johnathon Busing C.A.Joint Company Secretary
- Mr. Kieran Witt C.A.Joint Company Secretary